While the flagship South Korean index KOSPI is experiencing one of the deepest declines in its history, a real rally is unfolding on the alternative KOSDAQ exchange. Shares of HLB, SPG, and Peptron have risen more than 50% over the past month, showing a stark contrast with sentiment on the main market. This is not just a local anomaly, but a signal of a structural shift in investor preferences, as they seek refuge from turbulence in "blue chips."

KOSPI's fall and the flight to small caps

July was catastrophic for KOSPI: the index lost 22%, and from its peak on July 22, the drawdown reached 34%. A one-day rebound of nearly 18% in the last trading session of the month only partially recovered the losses. The main culprits behind the crash were credit ETFs tied to shares of tech giants like Samsung Electronics and SK Hynix. Regulators, trying to cool speculative fervor, raised the minimum cash deposit for trading these instruments from 10 million to 30 million won (KRW), leading to a 93% collapse in trading volumes.

However, instead of the expected market stabilization, we are witnessing a capital shift. Investors are massively withdrawing funds from the "heavyweights" and directing them into smaller companies on KOSDAQ. The KOSDAQ index rose for five consecutive trading days through August 6, ignoring the ongoing fluctuations of the main index. This is a classic "rotation" pattern, where fear of overvalued giants drives the search for new growth points.

Three success stories: from pharma to robotics

HLB's rise is tied to the dramatic saga surrounding the anticancer drug rivoceranib. On July 13, the FDA rejected approval for the third time, citing production issues at a Chinese partner. But just two days later, the regulator lifted restrictions on the plant, triggering a nearly 30% surge in the stock within a day. This is a vivid example of how volatility in the news flow can create powerful trading opportunities.

SPG, a manufacturer of high-precision motors and reducers, is steadily climbing thanks to its actuator project for humanoid robots. According to IBK Securities estimates, it is the only Korean company with a full range of high-precision reducers for humanoid robots. SPG already supplies products to Rainbow Robotics and is in preliminary talks with American partners, opening access to a rapidly growing market.

Peptron rose on August 3 amid rumors of possible involvement in the supply chain for anti-obesity drugs. Investors are betting that Korean manufacturers will take on production for the domestic market of Eli Lilly's monthly GLP-1-based drug. An official contract has not yet been signed, but the very potential of collaboration with a global pharma giant is already heating up interest.

My view: The current dynamics are not just a reaction to regulatory changes, but a systemic reassessment of risk appetite. While KOSPI is hostage to the AI cycle and fears of peak capital expenditure, KOSDAQ offers targeted stories with specific catalysts. However, investors should remember: the high volatility of such stocks is a double-edged sword. A 50% rise can be followed by an equally rapid correction at the slightest deterioration in fundamental news.